Log In
Print this Print this

Vitekta, elvitegravir (GS 9137)

Also known as: JTK-303

  Manage Alerts
Collapse Summary General Information
Company Japan Tobacco Inc.
DescriptionHIV integrase inhibitor
Molecular Target HIV integrase
Mechanism of ActionHIV integrase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection; Treat HIV-1 infection in adults without known mutations associated with resistance to elvitegravir
Regulatory Designation U.S. - Undisclosed Review (Treat HIV-1 infection);
EU - Standard Review (Treat HIV-1 infection);
Japan - Orphan Drug (Treat HIV-1 infection)
PartnerGilead Sciences Inc.;
Torii Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today